Company intelligence / Profile preview

One Biosciences

Ownership: Private
Development stage: Other

Overview

One Biosciences has developed a fully operational AI-powered single-cell analysis platform to identify novel precision oncology solutions. The company’s technology enables deep molecular profiling of difficult-to-treat cancers, aiming to discover new biomarkers and drug targets. As of mid-2025, the company has not yet advanced programs into clinical trials but plans real-life pilot studies with leading hospitals in 2025.

Therapeutic areas: Rare DiseasesOncology
Modalities: Single-cell analysis platformRNA-based therapies
Industry: Biotech

Partnerships

Institut CurieAmazon Web Services

Beyond the preview

Go deeper on One Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on One Biosciences.

Explore the full profile